Systematic review of NTRK 1/2/3 fusion prevalence pan-cancer and across solid tumours

Systematic review of NTRK 1/2/3 fusion prevalence pan-cancer and across solid tumours

Abstract NTRK gene fusions are rare somatic mutations found across cancer types with promising targeted therapies emerging. Healthcare systems face significant challenges in integrating these treatments, with uncertainty in prevalence and optimal testing methods to identify eligible patients. We per...

Cur síos iomlán

Sonraí bibleagrafaíochta
Príomhchruthaitheoirí:	Sophie O’Haire, Fanny Franchini, Yoon-Jung Kang, Julia Steinberg, Karen Canfell, Jayesh Desai, Stephen Fox, Maarten IJzerman
Formáid:	Alt
Teanga:	English
Foilsithe / Cruthaithe:	Nature Portfolio 2023-03-01
Sraith:	Scientific Reports
Rochtain ar líne:	https://doi.org/10.1038/s41598-023-31055-3

Míreanna comhchosúla

A scoping review and meta-analysis on the prevalence of pan-tumour biomarkers (dMMR, MSI, high TMB) in different solid tumours
de réir: Yoon-Jung Kang, et al.
Foilsithe / Cruthaithe: (2022-11-01)

Applicability of pan-TRK immunohistochemistry for identification of NTRK fusions in lung carcinoma
de réir: Simon Strohmeier, et al.
Foilsithe / Cruthaithe: (2021-05-01)

NTRK fusion in Japanese colorectal adenocarcinomas
de réir: Yuya Yamashiro, et al.
Foilsithe / Cruthaithe: (2021-03-01)

NTRK1 fusion in glioblastoma multiforme.
de réir: Jinkuk Kim, et al.
Foilsithe / Cruthaithe: (2014-01-01)

<i>NTRK</i> Fusions in 1113 Solid Tumors in a Single Institution
de réir: Heejin Bang, et al.
Foilsithe / Cruthaithe: (2022-06-01)

Clinicopathological findings of pediatric NTRK fusion mesenchymal tumors
de réir: Jeongwan Kang, et al.
Foilsithe / Cruthaithe: (2020-09-01)

Brazilian Expert Consensus for NTRK Gene Fusion Testing in Solid Tumors
de réir: Mariana Petaccia de Macedo, et al.
Foilsithe / Cruthaithe: (2023-09-01)

Correction: NTRK1 Fusion in Glioblastoma Multiforme
Foilsithe / Cruthaithe: (2014-01-01)

NTRK amplification occurs frequently in pan-TRK immunopositive dedifferentiated liposarcomas
de réir: Zoltán Lippai, et al.
Foilsithe / Cruthaithe: (2025-01-01)

Pre‐ and post‐treatment blood‐based genomic landscape of patients with ROS1 or NTRK fusion‐positive solid tumours treated with entrectinib
de réir: Rafal Dziadziuszko, et al.
Foilsithe / Cruthaithe: (2022-05-01)

Expert consensus on the diagnosis and treatment of NTRK gene fusion solid tumors in China
de réir: Chunwei Xu, et al.
Foilsithe / Cruthaithe: (2022-11-01)

Case report: Adult NTRK-rearranged spindle cell neoplasms with TPM3-NTRK1 fusion in the pelvic
de réir: Qiurui Cao, et al.
Foilsithe / Cruthaithe: (2024-01-01)

Implementing competing risks in discrete event simulation: the event-specific probabilities and distributions approach
de réir: Fanny Franchini, et al.
Foilsithe / Cruthaithe: (2023-10-01)

NTRK fusions in osteosarcoma are rare and non‐functional events
de réir: Baptiste Ameline, et al.
Foilsithe / Cruthaithe: (2020-04-01)

Molecular and clinicopathologic features of gliomas harboring NTRK fusions
de réir: Matthew Torre, et al.
Foilsithe / Cruthaithe: (2020-07-01)

Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population
de réir: C. B. Westphalen, et al.
Foilsithe / Cruthaithe: (2021-07-01)

Case Report: Identification of a novel NTRK3-AJUBA fusion co-existing with ETV6-NTRK3 fusion in papillary thyroid carcinoma
de réir: Qing-Xiang Yu, et al.
Foilsithe / Cruthaithe: (2023-04-01)

NTRK-rearranged spindle cell tumor with SPECC1L-NTRK3 fusion in the thoracic spine: a case report
de réir: Mi Zhou, et al.
Foilsithe / Cruthaithe: (2024-12-01)

NTRK Somatic Fusions and Tumor Agnostic Treatment in Pediatric Cancers
de réir: Emel Ünal, et al.
Foilsithe / Cruthaithe: (2022-11-01)

Dermoscopic Features of Spitz Tumor With LMNA-NTRK1 Fusion
de réir: Ben J. Friedman, et al.
Foilsithe / Cruthaithe: (2020-12-01)

Identification of NTRK gene fusions in lung adenocarcinomas in the Chinese population
de réir: Ruiying Zhao, et al.
Foilsithe / Cruthaithe: (2021-07-01)

NTRK-fused central nervous system tumours: clinicopathological and genetic insights and response to TRK inhibitors
de réir: Eric Eunshik Kim, et al.
Foilsithe / Cruthaithe: (2024-07-01)

Author Correction: Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population
de réir: C. B. Westphalen, et al.
Foilsithe / Cruthaithe: (2021-09-01)

Genomic Features of Solid Tumor Patients Harboring ALK/ROS1/NTRK Gene Fusions
de réir: Yinghuan Dai, et al.
Foilsithe / Cruthaithe: (2022-06-01)

Critical domains for NACC2-NTRK2 fusion protein activation.
de réir: Wei Yang, et al.
Foilsithe / Cruthaithe: (2024-01-01)

NTRK Fusions in a Sarcomas Series: Pathology, Molecular and Clinical Aspects
de réir: Vasiliki Siozopoulou, et al.
Foilsithe / Cruthaithe: (2022-05-01)

<i>NTRK</i> Fusions in Sarcomas: Diagnostic Challenges and Clinical Aspects
de réir: Vasiliki Siozopoulou, et al.
Foilsithe / Cruthaithe: (2021-03-01)

NTRK Fusions and TRK Inhibitors: Potential Targeted Therapies for Adult Glioblastoma
de réir: Yuekun Wang, et al.
Foilsithe / Cruthaithe: (2020-11-01)

Case report: STRN3-NTRK3 fusion in uterine sarcoma with spleen metastasis: a new variant in the spectrum of NTRK-rearranged tumors
de réir: Piergiuseppe Colombo, et al.
Foilsithe / Cruthaithe: (2024-11-01)

Prevalence of neurotrophic tropomyosin receptor kinase (NTRK) fusion gene positivity in patients with solid tumors in Japan
de réir: Eiji Nakata, et al.
Foilsithe / Cruthaithe: (2024-06-01)

Tumor Mutation Burden Survey of AACR GENIE Database Revealed NTRK (NTRK+) and RET (RET+) Fusions Positive Colorectal Carcinoma (CRC) as Distinct Subsets
de réir: Zhaohui Liao Arter, et al.
Foilsithe / Cruthaithe: (2025-02-01)

A case of thyroid carcinoma with mucinous features harboring ETV6-NTRK3 fusion: Expanding the morphologic spectrum of NTRK-rearranged thyroid carcinoma
de réir: Khaled A. Murshed, et al.
Foilsithe / Cruthaithe: (2022-06-01)

Detection of <i>NTRK</i> Fusions and TRK Expression and Performance of pan-TRK Immunohistochemistry in Routine Diagnostics: Results from a Nationwide Community-Based Cohort
de réir: Bart Koopman, et al.
Foilsithe / Cruthaithe: (2022-03-01)

Use of Diagnostic Algorithms for *NTRK* Fusion-Positive Tumors in Pathology Institutes in Switzerland
de réir: Holger Moch, et al.
Foilsithe / Cruthaithe: (2021-03-01)

BPI-28592 as a novel second generation inhibitor for NTRK fusion tumors
de réir: Jin Sheng, et al.
Foilsithe / Cruthaithe: (2024-09-01)

Systematic population-based identification of NTRK and RET fusion-positive thyroid cancers
de réir: Markus Eszlinger, et al.
Foilsithe / Cruthaithe: (2023-01-01)

Recurrent EGFR alterations in NTRK3 fusion negative congenital mesoblastic nephroma
de réir: Li Lei, et al.
Foilsithe / Cruthaithe: (2020-08-01)

Use of Diagnostic Algorithms for NTRK Fusion-Positive Tumors in Pathology Institutes in Switzerland
de réir: Holger Moch, et al.
Foilsithe / Cruthaithe: (2021-03-01)

Entrectinib approval by EMA reinforces options for ROS1 and tumour agnostic NTRK targeted cancer therapies
de réir: Salvatore Siena, et al.
Foilsithe / Cruthaithe: (2020-10-01)

Secretory carcinoma of major and minor salivary glands with ETV6-NTRK3 gene fusion: overcoming misdiagnosis in the era of tumour-agnostic therapy with TRK inhibitors
de réir: Monika Durzyńska, et al.
Foilsithe / Cruthaithe: (2023-08-01)